TFR Global Appointed As Approved Brokerage For Merlin Biotech

Merlin Biotechnologies are pleased to confirm that TFR Global are now appointment as the company's approved brokerage to over-see their 3 rounds of private placement financing which will start early next year. Merlin Biotechnologies, a Canadian based bio-tech company whose focus is primarily on researching and developing clinically approved medicines, using various strains of marijuana, intend to float on the NYSE in the 3rd quarter of 2020.

Their stage 1 round of financing has been set at a price of U.S. $0.85 per share, with stage 2 set at U.S. $1.05 per share and stage 3 at U.S. $1.25 per share. TFR Global's appointment will allow them to offer investors Merlin Biotechnologies' IPO stock, throughout all 3 rounds of the financing at the above pricing, and it is expected that it will take no more than 5 months to complete all of the required allocations. Furthermore, TFR Global will be assisting and over-seeing, if necessary, any potential take-over offers that Merlin Biotechnologies may receive before their scheduled flotation takes place. TFR Global's extensive presence and client base will allow for investors to acquire these pre-IPO stock allocations in Merlin Biotechnologies at entry level positions of between U.S. $10,000 and U.S. $30,000 per client, depending upon allocation availability.

"We are extremely excited about being able to offer our clients, old and new, this fantastic opportunity with one of Canada's leading marijuana bio-tech companies. The marijuana sector, particularly the medicinal market, is an extremely exciting investment sector to be involved with and our past experiences have shown us it to be a profitable one too," said Dennis Tillman, Managing Director with TFR Global. "Also, the ethical side that this sector offers is something that a lot of investors find as much of an appeal as the returns it achieves as the clinical advancements being made are now proving to be of enormous benefit to an ever-growing number of people worldwide," Dennis Tillman added.

Due to TFR Global's anticipated investment demand relating to this opportunity they have set up a strategic team of senior personnel to ensure that all allocations are made within the least amount of time possible.

https://www.tfrglobal.com
https://merlinbiotech.com

Merlin Biotechnologies
Southbridge Business Park,
East Kent Avenue,
Vancouver, BC,
V5X 0B2,
Canada

As a pharmaceutical biotechnology research company we focus on the discovery and development of modern and innovative cannabinoid medical therapies and medicines to treat diseases that have been ailing patients worldwide. Our belief that medicinal marijuana can help treat these diseases is backed by our extensive research from our dedicated team of individuals that have been in this branch of science for most of their professional lives.

Merlin Biotechnologies researches and develops marijuana-based therapeutic products through modern bio-technology from the marijuana plant which has a clinically proven multitude of healing properties and benefits to the human body.

This release was published on openPR.